UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000064
Receipt number R000000108
Scientific Title Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with BCR-ABL-Negative Acute Lymphoblastic Leukemia (JALSG ALL202-U)
Date of disclosure of the study information 2005/08/17
Last modified on 2011/10/27 11:31:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with BCR-ABL-Negative Acute Lymphoblastic Leukemia (JALSG ALL202-U)

Acronym

Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with ALL (JALSG ALL202-U)

Scientific Title

Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with BCR-ABL-Negative Acute Lymphoblastic Leukemia (JALSG ALL202-U)

Scientific Title:Acronym

Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with ALL (JALSG ALL202-U)

Region

Japan


Condition

Condition

Acute lymphoblastic leukemia

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose of this study is to investigate efficacy and safety of treating adult ALL patients with an intensive pediatric regimen.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Disease-free survival at 3 years

Key secondary outcomes

Toxicity, the rate of complete remission


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Induction therapy (Week 1-5): MTX, PSL, DEX, VCR, THP-ADR, CPM, L-ASP, Ara-C, HDC. Consolidation therapy (Week 6-9): CPM, THP-ADR, Ara-C, 6MP, MTX, HDC. Sanctuary therapy (Week 10-11): MTX, Ara-C, HDC. Reinduction therapy (Week 12-15): VCR, THP-ADR, CPM, L-ASP, PSL, MTX, Ara-C, HDC. Reconsolidation therapy (Week 16-19): CPM, THP-ADR, Ara-C, 6MP, MTX, HDC. Maintenance therapy (Week 20-25): MTX, 6MP, CPM, THP-ADR, Ara-C, 6MP, HDC. Maintenance therapy (Week 26-29, 46-49, 66-69, 86-89): VCR, CPM , L-ASP, PSL. Maintenance therapy (Week 30-35, 40-45, 50-55, 60-65, 70-75, 80-85, 90-95): MTX, 6MP, Ara-C, HC. Maintenance therapy (Week 36-39, 56-59, 76-79, 96-98): VCR, THP-ADR, L-ASP, PSL.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit

25 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Previously untreated BCR-ABL-negative ALL (2) Age between 15 and 24 years (3) Performance status between 0 and 3 (ECOG criteria) (4) Adequate functioning of the liver (serum bilirubin level < 2.0 mg/dL), kidneys (serum creatinine level < 2.0 mg/dL), and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs) (5) Written informed consent to participate the trial

Key exclusion criteria

(1) Uncontrolled active infection (2) Another severe and/or life-threatening disease (3) Positive for HIV antibody and/or HBs antigen tests (4) Another primary malignancy which is clinically active and/or requires medical interventions (5) Pregnant and/or lactating woman (6) Past history of renal failure

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoki Naoe

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Hematology and Oncology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

TEL

052-744-2145

Email



Public contact

Name of contact person

1st name
Middle name
Last name Fumihiko Hayakawa

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Hematology and Oncology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan

TEL

052-744-2145

Homepage URL

http://www.jalsg.jp/

Email

bun-hy@med.nagoya-u.ac.jp


Sponsor or person

Institute

Japan Adult Leukemia Study Group

Institute

Department

Personal name



Funding Source

Organization

Japan: Ministry of Health, Labor and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NCT00131053

Org. issuing International ID_1

Clinicaltrials.gov

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 08 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2002 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2002 Year 09 Month 01 Day

Last follow-up date

2011 Year 09 Month 01 Day

Date of closure to data entry

2011 Year 12 Month 01 Day

Date trial data considered complete

2012 Year 03 Month 01 Day

Date analysis concluded

2012 Year 08 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 08 Month 17 Day

Last modified on

2011 Year 10 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000108


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name